The first question to ask when joining a pre-product deep technology company is not how strong the IP is. It is where the IP is. And who is managing it. At one company I served, it took me a week to answer that question. When the answer finally came together, it still did not make sense.
Four law firms. Seven patent families. Two distinct scientific programs. Claims filed across the United States, Europe, Japan, China, and several other jurisdictions. A licensed patent from a major defense contractor with a term quietly counting down. A university license bundled with its own outside counsel, reimbursed by the company under an agreement nobody had reviewed recently. Each firm had been added for a legitimate reason at a legitimate moment. Nobody had ever been asked to make them work together.
Some people look at that situation and see a mess. I see uncaptured value.
This pattern is not unique to life sciences. A semiconductor startup accumulates IP counsel the same way: the boutique that understood the original chip architecture, the large firm brought in by the Series B lead, the university agreement that came with its own preferred attorneys, the acquisition that added a fourth firm managing legacy patents nobody fully understood. An AI infrastructure company building on licensed foundation models faces an equivalent tangle of ownership, sublicense rights, and prosecution strategies never designed to work in parallel. The details differ. The structural problem, and the opportunity inside it, are identical.
For a pre-product company, the patent portfolio is not a legal record. It is the balance sheet. If you cannot read it clearly, you cannot price the company accurately. And you cannot ask anyone else to.
The Mandate
Someone who had been a friend to the company for years, both with his money and his scientific endorsement, pulled me aside not long after I joined. He had watched the asset accumulate promise and disorder in roughly equal measure. His message was direct: these people are making a mess of a good thing. Go clean it up. Use your common sense. Be a businessman.
That instruction shaped everything that followed. Not procedural frameworks or institutional vocabulary. The business instinct. What does this asset actually need to be worth something to the next investor? What stands between where this company is and where it could be? Those are not legal questions. They are operator questions, and they have operator answers.
My role over the next two and a half years spanned functions that resist a single job title. Senior advisor. De facto chief strategy officer. Finance counterpart to the institutional investors who needed someone inside the company who thought in their language. Sounding board for scientists making decisions that were nominally technical but actually organizational. In the plainest terms: a fixer. The law degree was a tool. The job was to build value.
The Scientists
Daniel had founded the company on a licensed patent and a scientific conviction he had been refining for two decades. MD, PhD in medicinal chemistry, lived near Stanford, thought faster than most rooms could follow. He was also, on questions where he had already formed a view, not easy to redirect. His relationship with his original patent counsel had been contentious for years. He found them intellectually unsatisfying. He had never fully trusted them. He had also never replaced them.
Marcus was a retired professor in the precise sense that he had left his faculty position, and in no other sense. He had joined to advance a complementary biological program he had spent his career developing, and he brought with him a preferred attorney at one of the larger firms, a senior associate whose fluency in biology Marcus valued and was not inclined to give up. In a meeting, Marcus would begin answering a question and forty-five minutes later be somewhere deep in the literature. This was genuinely interesting. At $1,700 an hour for outside counsel, it was also genuinely expensive.
The Consolidation
The right consolidation target was a partner at one of the existing firms whose background was in medicinal chemistry. Senior enough to make decisions. Deep enough on the science to hold her own with Daniel. Experienced enough to absorb seven patent families without losing the thread.
Daniel's first reaction, offered without having read her work: "I don't think she's right for this." The assessment was confident and specific, which meant it was also movable, if you found the right lever.
The lever was the science. When they finally sat together, she pushed back on one of his prosecution assumptions. Not procedurally. Chemically. He stopped mid-sentence. Thought about it. Asked a follow-up question. The conversation ran two hours. He called the next morning: "I think the consolidation makes sense."
That reversal was not incidental to the outcome. It was the precondition for it. A consolidation Daniel tolerated but did not believe in would have collapsed at the first disagreement. The job was to earn his conviction, not his compliance. The right operator creates the conditions for the right meeting and then steps back.
Marcus required a different approach. His loyalty to his preferred attorney was real and not easily argued away. What moved him was a reframe: his program was no longer a standalone initiative. It was part of a combined platform, and a combined platform needed counsel who could hold both programs simultaneously. His preferred attorney, however talented, was a senior associate without the standing to make that kind of strategic judgment.
"Think beyond your program," I told him. "Think about the platform. That is where the value lives." He understood. He came along.
Compliance is not alignment. A founder who tolerates a decision will relitigate it under pressure. Earning genuine conviction takes longer. It is also the only version that holds.
The Inventory
Nine months of methodical work followed. Files tracked down from each departing firm. Engagement letters closed. Foreign associate relationships transferred across a dozen jurisdictions. Maintenance schedules reconciled from four different systems. Every claim set mapped against both scientific programs to surface gaps, overlaps, and prosecution decisions made without visibility into the full picture.
Once the migration was complete, a standing cadence was established: biweekly calls with the lead partner, structured separately for each scientific program, with both technical teams present. Active decision-making in real time, not status reporting. A device program that had emerged as a third coverage area was folded into the same structure. Within six months, the portfolio that had been unreadable was producing something a prospective investor could rely on.
That was not a legal achievement. It was a business one.
The Financing
The consolidation had been intentional from the start, not as a governance exercise but as the first step in a financing strategy. A defensible portfolio supports a defensible valuation. A defensible valuation anchors a structured round. That was the sequence, and it played out as designed.
A third-party valuation firm, engaged once the portfolio was under unified management, produced an assessment grounded in actual coverage and prosecution strategy rather than founder optimism. Several investors noted afterward that the valuation felt earned rather than asserted. That is a rarer compliment than it should be, and it mattered to the round.
The structure threaded a needle between two existing institutional investors protecting their positions and a new investor who needed economics that justified entering at a higher valuation. The solution was a simultaneous two-part transaction.
The existing investors participated in a priced round, buying a new series of preferred shares with a two-times liquidation preference on their new money. They would recover up to twice their incremental investment before proceeds flowed to common shareholders, giving them downside protection while keeping them aligned with the company's progress. The new investor came in through a convertible note structured to convert automatically into that same preferred stock, at terms calibrated to land him at roughly thirty percent of the company on a fully diluted basis.
The valuation cap on the note reflected the portfolio's actual defensibility. Not a promotional number. The new investor was buying a cleaner, better-documented asset than had existed two years earlier, and the price said so plainly. All three institutional investors accepted the logic. The company closed with cash, a stable cap table, and a thirty percent increase in enterprise value.
No new science. No product milestone. No additional capital consumed. Thirty percent increase in enterprise value, built entirely on the professional infrastructure work that preceded it.
The Pattern
PE firms encounter this situation across every sector that runs on intangible assets. A founder-led semiconductor company acquired at Series C has patent counsel in three cities, chosen over seven years for reasons that no longer add up to a strategy. An enterprise software company has IP exposure nobody has mapped since the seed round. An AI infrastructure company has upstream rights entanglements the deal team flagged and the portfolio company has not resolved.
The value creation sequence is the same in each case. Take an honest inventory of what actually exists. Build the professional infrastructure to manage it. Use that infrastructure to support a financing, a partnership, or an exit on terms that reflect the asset's true quality rather than its surface disorder.
The prerequisite is always the alignment work that does not appear on any invoice: the founder moved from dismissal to conviction, the scientist brought from his program to the platform, the institutional energy directed toward execution rather than drift. That work is not soft. It is the hardest part of the job, and the part most likely to determine whether the governance investment produces a return or produces a well-organized set of files nobody can act on.
Some people look at a fractured portfolio and see a mess. The ones who create value see it differently.
Clarity before capital. Governance before growth. Two and a half years, four firms reduced to one, thirty percent increase in enterprise value. Built on nothing more exotic than a businessman's common sense applied to a problem everyone else had decided to live with.